Kyntra Bio Reports Q1 2026 Earnings and Clinical Trial Results
Kyntra Bio (NASDAQ: KYNB) reported first-quarter earnings on May 11, 2026. The company posted a net loss of $15.1 million or $3.74 per share for the quarter compared to a prior-year loss of $16.8 million or $4.15 per share. Total revenue increased slightly year-over-year but remained low at $3.7 million, while operating costs and expenses were flat at $17.6 million.
Topics: cash_position clinical_trials net_loss operating_costs revenue